Charge Card Market Size, Trends And Overview Report 2024-2033 | Analysis, Growth, Demand

The Charge Card Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Charge Card Market:

https://www.thebusinessresearchcompany.com/report/charge-card-global-market-report

According to The Business Research Company’s Charge Card Global Market Report 2024, The charge card market size has grown marginally in recent years. It will grow from $1.99 billion in 2023 to $2.02 billion in 2024 at a compound annual growth rate (CAGR) of 1.4%. The growth in the historic period can be attributed to emergence of electronic payments, convenience and security, travel and entertainment, rewards programs.

The charge card market size is expected to see marginally grown in the next few years. It will grow to $2.27 billion in 2028 at a compound annual growth rate (CAGR) of 3.0%. The growth in the forecast period can be attributed to digital payments, contactless payments, online shopping, security and fraud prevention. Major trends in the forecast period include digital transformation, contactless payments, sustainability and esg, business charge cards, travel charge cards.

The lack of a pre-set spending limit and greater flexibility in spending contributed to the growth of the charge card market. Charge cards offer financial flexibility with no pre-set spending limit on the purchase, which means more buying power. Additionally, charge cards offer premium rewards, maximize reward points based on spending patterns, and also offer a variety of travel and purchase protections. For instance, American Express offers complimentary airport lounge access, hotel room upgrades, travel insurance, and much more. Customers will be able to improve their credit score by using charge cards responsibly and paying on time every month. A charge card allows a customer to organize personal events, dining reservations, golf bookings, movie, and theatre ticket bookings, and enjoy exclusive rates and discounts with leading airlines. These factors boosted demand for charge card services, and this, in turn, drove the charge card market. However, having no pre-set spending limit does not mean unlimited spending. The purchasing power is adjusted based on the use of the card, payment history, credit record, financial resources, and other factors. This, in turn, will assist the customer in developing financial discipline the charge card market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=4001&type=smp

The charge card market covered in this report is segmented –

1) By Type: Gold Card, Platinum Card, Plum Card, Business Gold Card, Business Platinum Card, Other Types

2) By Institution Type: Banking Institutions, Non-Banking Institutions

3) By End User: Retail, Corporate, Government/Public Sector

Major companies in the checkpoint inhibitor market are forming partnerships or collaborations for the development of advanced technologies such as bifunctional fusion proteins or Y-trap. Most patients with cancer do not respond to immune checkpoint inhibitors. To make immunotherapies more effective, a group of researchers has developed the bifunctional fusion protein or Y-trap. This drug is created by fusing a receptor for a protein called TGF-beta that targets checkpoint proteins such as PD-L1 or CTLA-4. Y- Trap targets both a checkpoint inhibitor and TGF-beta and gives a more effective way to block the immune suppression and destroys the cancer cells. Merck, a prominent science and technology group, and GSK, a research-based global healthcare company, have announced that they have entered into a global strategic partnership to jointly create and market M7824 (bintrafusp alfa). M7824 is an investigational bi-functional fusion protein immunotherapy that is currently in clinical research, including possible registration trials, for various difficult-to-treat cancers. This includes a Phase II study to investigate M7824 compared to pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). In another instance, in June 2021, GSK plc, a UK-based pharmaceutical industry company, entered into a collaboration with ITeos Therapeutics, a US-based biotech company. With collaboration, both companies aim to accelerate the development and commercialization of EOS-448. Combine GSK’s expertise in immuno-oncology with iTeos’ expertise in TIGIT biology and share the risk and reward of developing and commercializing EOS-448.

The charge card market report table of contents includes: